GlassScriptPhysician profile
Annie Gonzalez
NPI 1033418546
$44,814.01
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $765 · 2021: $536 · 2022: $480 · 2023: $783 · 2024: $27K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28,290.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $40,134.12 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $817.69 | 2019-2024 | |
| Allergan, INC. | $622.25 | 2019-2022 | |
| Abbvie INC. | $438.70 | 2019-2024 | |
| Merz North America, INC. | $432.78 | 2019-2023 | Xeomin |
| Lilly USA, LLC | $335.63 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $320.96 | 2019-2024 | |
| Journey Medical Corporation | $262.66 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $178.64 | 2019-2023 | Absorica Ld, Winlevi, Blu-U |
| Regeneron Healthcare Solutions, INC. | $146.85 | 2019-2023 | Dupixent |
| Pfizer INC. | $144.01 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $123.52 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.05 | 2019-2025 | Arazlo, Jublia, Cabtreo |
| Incyte Corporation | $110.00 | 2023-2024 | Opzelura |
| Almirall LLC | $96.39 | 2019-2023 | Seysara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $67.01 | 2019-2023 | |
| Janssen Biotech, INC. | $54.38 | 2023 | Tremfya |
| Dermavant Sciences, INC. | $44.11 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $41.39 | 2023 | |
| Sebela Pharmaceuticals INC. | $33.68 | 2019 | |
| Genzyme Corporation | $33.39 | 2024 | |
| Leo Pharma INC. | $29.09 | 2019 | |
| Dusa Pharmaceuticals, INC. | $24.96 | 2019 | |
| Biofrontera INC. | $24.09 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.79 | 2023 | Spevigo |
| Promius Pharma LLC | $23.18 | 2019 | |
| Dermira, INC. | $22.34 | 2020 | |
| Aclaris Therapeutics, INC. | $21.53 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.40 | 2023 | Ycanth |
| Alexion Pharmaceuticals, INC. | $19.19 | 2025 | Strensiq |
| Celgene Corporation | $19.18 | 2019 | |
| Epi Health, LLC | $14.29 | 2019 | |
| Organon LLC | $10.76 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.